These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10852693)

  • 41. [Use of venofer for iron deficiency correction in patients undergoing programmed hemodialysis].
    Fesiuk AF; Mordik AI; Borisova EV; Borisov AV; Lovchinskiĭ EV
    Ter Arkh; 2003; 75(8):59-61. PubMed ID: 14520854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The generation of non-dextran intravenous iron: is iron dextran obsolete?
    Lewis MJ; Swan SK
    Semin Dial; 2000; 13(1):9-10. PubMed ID: 10740666
    [No Abstract]   [Full Text] [Related]  

  • 43. Trends in intravenous iron use among dialysis patients in the United States (1994-2002).
    St Peter WL; Obrador GT; Roberts TL; Collins AJ
    Am J Kidney Dis; 2005 Oct; 46(4):650-60. PubMed ID: 16183420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of iron in patients on chronic dialysis: mistake and misconceptions.
    Sakiewicz P; Paganini E
    J Nephrol; 1998; 11(1):5-15. PubMed ID: 9561479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron management in end-stage renal disease.
    Fishbane S; Maesaka JK
    Am J Kidney Dis; 1997 Mar; 29(3):319-33. PubMed ID: 9041207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maintaining iron balance with total-dose infusion of intravenous iron dextran.
    Case G
    ANNA J; 1998 Feb; 25(1):65-8. PubMed ID: 9543911
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Achieving target hematocrit in dialysis patients: new concepts in iron management.
    Nissenson AR
    Am J Kidney Dis; 1997 Dec; 30(6):907-11. PubMed ID: 9398140
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pumping iron: revisiting risks, benefits and strategies in treatment of iron deficiency in end-stage renal disease.
    Singh N; Agarwal AK
    Clin Nephrol; 2012 Mar; 77(3):188-94. PubMed ID: 22377249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
    Coyne DW; Sims A; Bingel B
    Nephrol Nurs J; 2008; 35(6):583-7. PubMed ID: 19260610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment.
    Senger JM; Weiss RJ
    ANNA J; 1996 Jun; 23(3):319-23; discussion 324-5. PubMed ID: 8716991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
    Dimković N
    Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
    Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial.
    Singh H; Reed J; Noble S; Cangiano JL; Van Wyck DB;
    Clin J Am Soc Nephrol; 2006 May; 1(3):475-82. PubMed ID: 17699248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.
    Nyvad O; Danielsen H; Madsen S
    Lancet; 1994 Nov; 344(8932):1305-6. PubMed ID: 7968018
    [No Abstract]   [Full Text] [Related]  

  • 57. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin.
    Post JB; Wilkes BM; Michelis MF
    Int Urol Nephrol; 2006; 38(3-4):719-23. PubMed ID: 17106764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure.
    Zilberman M; Silverberg DS; Bits I; Steinbruch S; Wexler D; Sheps D; Schwartz D; Oksenberg A
    Am Heart J; 2007 Nov; 154(5):870-6. PubMed ID: 17967592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progress in intravenous iron treatment.
    Marx JJ
    Arzneimittelforschung; 2010; 60(6a):341-4. PubMed ID: 20648925
    [No Abstract]   [Full Text] [Related]  

  • 60. [Results of the explicit health guaranties program to correct anemia of end stage renal disease patients in dialysis].
    González F F
    Rev Med Chil; 2013 May; 141(5):568-73. PubMed ID: 24089270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.